Ascendis Pharma A/S Announces Positive Top-line Results from Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency
July 30, 2015 at 07:08 AM EDT
Ascendis Pharma A/S (Nasdaq: ASND) today announced positive top-line results from a six-month Phase 2 study to evaluate the safety and ...